Skip to main content
. 2017 Oct 16;9(12):1629–1645. doi: 10.15252/emmm.201607445

Figure 3. Concomitant macrophage accumulation and in situ switch from M1 to M2 phenotype with blood vessel abnormalities during glioma growth.

Figure 3

  1. MHCII and MRC1 immunohistochemistry on a section of 3‐ to 5‐week growth glioma implanted in ROSAmT/mG ::Pdgfb‐iCre mouse. M1 macrophages, preferentially located in hypoxic area, are abundant at 3 weeks and their number decreases at 5 weeks. M2 macrophages, preferentially located around blood vessels, are present at a low level at 3 weeks and their number increases at 5 weeks.
  2. Macrophage quantification during glioma growth (n = 5 mice per group).
  3. MHCII and MRC1 macrophage population FACs analysis in 2‐, 3‐, 4‐, and 5‐week glioma (subsets in gated CD11b+ cells; n = 3 mice per group).
  4. Correlation analysis of M2‐like macrophages accumulation (MRC1 positive) with vessel dysmorphia over glioma growth (n = 12 mice).
  5. MRC1 immunohistochemistry on 3‐week growth glioma in ROSAmTmG ::Pdgfb‐iCre mouse following MHCII‐FITC labeled IV injection at 6 or 24 h (5‐μm depth stack). Note the segregation of MRC1 and MHCII cell labeling at 6 h and the overlapping (examples pointed with arrow heads) of these two markers at 24 h (n = 5 mice per group).
Data information: Statistical analysis: (B) one‐way ANOVA followed by multiple comparisons Tukey's test; (D) Spearman's correlation test; (E) t‐test. Error bars: mean ± SD. Scale bars: (A) 200 μm; (E) 50 μm.